Anti-CHD2 (aa 260-476) polyclonal antibody

Ab-initio calculations have been performed at the HF/6-31G** and HF/6-31++G(d,p) levels to study the conformational dependence of the geometry and the vibrational frequencies of three hydrogen/deuterium (d0, d1, d2) isotopomers of nitromethane. The Raman gas-phase spectra of these compounds are also presented. They compare well with the infrared ones and the theoretical prediction. The calculated overall zero-point vibrational energy of both d1 and d2 isotopomers presents an angular dependence of the form V2 cos(2theta) + V4 cos(4theta). It contributes significantly to the methyl torsion potential and causes two different equilibrium positions for the d1 (eclipsed) and d2 (staggered) methyl groups. The vibrational origin of the V2 and V4 pseudopotential terms of the rotational potential of the partially deuterated methyl groups is thus confirmed. The close correspondence between calculated and experimental results shows that theoretical calculations can be a convenient alternative to analyze the lone CH or CD stretching spectra of the partially methyl groups.

Pediatric refractory epilepsy is a broad phenotypic spectrum with great genetic heterogeneity. Next-generation sequencing (NGS) combined with Sanger sequencing could help to understand the genetic diversity and underlying disease mechanisms in pediatric epilepsy. Here, we report sequencing results from a cohort of 172 refractory epilepsy patients aged 0-14 years. The pathogenicity of identified variants was evaluated in accordance with the American College of Medical Genetics and Genomics (ACMG) criteria. We identified 43 pathogenic or likely pathogenic variants in 40 patients (23.3%). Among these variants, 74.4% mutations (32/43) were de novo and 60.5% mutations (26/43) were novel. Patients with onset age of seizures >= 12 months had higher yields of deleterious variants compared to those with onset age of seizures > 12 months (P = 0.006). Variants in ion channel genes accounted for the greatest functional gene category (55.8%), with SCN1A coming first (16/43). 81.25% (13/16) of SCN1A mutations were de novo and 68.8% (11/16) were novel in Dravet syndrome. Pathogenic or likely pathogenic variants were found in the KCNQ2, STXBP1, SCN2A genes in Ohtahara syndrome. Novel deleterious variants were also found in West syndrome, Doose syndrome and glucose transporter type 1 deficiency syndrome patients. One de novo MECP2 mutation were found in a Rett syndrome patient. TSC1/TSC2 variants were found in 60% patients with tuberous sclerosis complex patients. Other novel mutations detected in unclassified epilepsy patients involve the SCN8A, CACNA1A, GABRB3, GABRA1, IQSEC2, TSC1, VRK2, ATP1A2, PCDH19, SLC9A6 and CHD2 genes. Our study provides novel insights into the genetic origins of pediatric epilepsy and represents a starting-point for further investigations into the molecular pathophysiology of pediatric epilepsy that could eventually lead to better treatments.